Ticker: ROG.SW

Roche (SIX:ROG) reveals strong Phase III trial results for fenebrutinib, an oral MS drug that cuts relapse rates and slows disability, potentially addressing both major MS forms.

Roche (ROG) to buy 89bio (ETNB) in a cash tender at $14.50/sh plus a non‑tradable CVR up to $6, valuing the deal at ~$2.4B upfront and up to ~$3.5B for pegozafermin (FGF21) targeting MASH.